Search results
Google's Demis Hassabis is the man tasked with turning bleeding-edge AI research into profits
NBC Los Angeles· 20 hours agoDemis Hassabis is emerging as the face of Google's AI effort and will take the stage at this week's...
Diacerein, Resveratrol, Botulinum Toxin Disappoint in Knee OA
Medscape· 6 days agoData do not back the use of diacerein or resveratrol for managing the pain of knee osteoarthritis...
Decoding BeiGene Ltd (BGNE): A Strategic SWOT Insight
GuruFocus.com via Yahoo Finance· 5 days agoStrategic partnerships with industry giants like Amgen and Novartis have bolstered its commercial...
Google DeepMind debuts huge AlphaFold update and free proteomics-as-a-service web app
TechCrunch· 6 days agoGoogle DeepMind has taken the wraps off a new version of AlphaFold, their transformative machine...
IPC Develops Consensus on Generalized Pustular Psoriasis
Medscape· 6 days agoThe IPC's definition and diagnostic criteria for GPP minimized the complexity of clinical...
Legend Biotech 1Q Loss Narrows with Higher Carvykti Sales
Morningstar· 18 hours agoBy Dean Seal Legend Biotech narrowed its loss in the first quarter as revenue climbed on higher sales of its multiple myeloma treatment Carvykti. The cell therapy company posted a loss of $59.8 million, or 16 cents a share, compared with
DeepMind CEO Targets $100 Billion-Plus AI Drug Discovery Business With AlphaFold
Bloomberg via Yahoo Finance· 6 days ago(Bloomberg) -- Google DeepMind has released a new version of AlphaFold, a landmark tool for...
Swiss Market Ends Marginally Up After Lackluster Session
RTT News· 12 hours agoSwiss stocks ended slightly up on Monday after a lackluster session as investors refrained from making significant moves amid a lack of triggers..
Big Pharma layoffs continue, as Bristol-Myers Squibb cuts 2,200 jobs, $1.5B in costs
BenefitsPRO· 4 days agoAt a time when drugmakers Eli Lilly & Co. and Novo Nordisk are scrambling to meet demand for their...
3 Biotech Stocks to Sell in May Before They Crash & Burn
InvestorPlace· 4 days agoAlthough 5% up over one year, the S&P Biotechnology Select Industry Index is down .22% year-to-date....
